Qube Research & Technologies (QRT)’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.21M Sell
6,600
-101,900
-94% -$18.8M ﹤0.01% 2411
2025
Q4
$19.1M Sell
108,500
-17,600
-14% -$2.88M 0.02% 940
2025
Q3
$17.7M Sell
126,100
-83,200
-40% -$11.2M 0.02% 959
2025
Q2
$26.3M Sell
209,300
-401,000
-66% -$50M 0.03% 739
2025
Q1
$83.5M Buy
610,300
+273,500
+81% +$39.1M 0.1% 261
2024
Q4
$51.5M Buy
336,800
+271,400
+415% +$45.8M 0.07% 372
2024
Q3
$12.7M Sell
65,400
-70,800
-52% -$14.8M 0.02% 897
2024
Q2
$31.6M Buy
136,200
+118,600
+674% +$25.8M 0.05% 438
2024
Q1
$3.8M Buy
+17,600
New +$4.12M 0.01% 1392
2023
Q4
Sell
-18,800
Closed -$4.83M 4344
2023
Q3
$4.83M Buy
+18,800
New +$5.03M 0.01% 947

Other funds holding BIIB

Qube Research & Technologies (QRT)'s BIIB Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Biogen (BIIB) in Q1 2026: 212,921 shares worth $39M. The stake represents 0.04% of the portfolio and ranks #532 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in BIIB as recently as Q3 2025.

Qube Research & Technologies (QRT) first reported a position in BIIB in Q1 2018 and has held it in 24 quarters since. The position peaked at $168M in Q1 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Qube Research & Technologies (QRT) held 212,921 shares of Biogen worth $39M as of Q1 2026.
  • Biogen was a new Qube Research & Technologies (QRT) position in Q1 2026.
  • Biogen made up 0.04% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #532 holding.
  • Qube Research & Technologies (QRT) first reported a position in Biogen in Q1 2018 and has held it in 24 quarters since.
  • Qube Research & Technologies (QRT)'s Biogen position peaked at $168M in Q1 2025.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.